Lung Cancer Clinical Trial

Clinical Trial Finder Lung Cancer Trials

Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer

See Locations Near You

Summary

A phase I-II dose ranging study of BMS-275183 (oral taxane) in combination with pemetrexed (Alimta) in patients with recurrent Non-Small Cell Lung Cancer (NSCLC). The safety and efficacy of this combination will be studied.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Advanced or metastatic pretreated NSCLC
Measurable disease
Adequate hematologic, hepatic and renal functions.
ECOG Performance Status 0-2

Exclusion Criteria:

Inability to swallow capsules
Recent significant cardiovascular disease
Women who are pregnant or breastfeeding

Study is for people with:

Lung Cancer

Phase:

Phase 1

Study ID:

NCT00103831

Recruitment Status:

Completed

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Local Institution
Denver Colorado, , United States
Local Institution
Rochester Minnesota, , United States
Local Institution
Toronto Ontario, , Canada

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 1

Study ID:

NCT00103831

Recruitment Status:

Completed

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
Clinical Trials Can be Life-Saving for Some
When Should I Consider Clinical Trials?
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider